Adipose tissue immune response: Novel triggers and consequences for chronic inflammatory conditions

Inflammation

Volumn 37, Issue 4, 2014, Pages 1337-1353

  Ghigliotti, Giorgio ^a   Barisione, Chiara ^a   Garibaldi, Silvano ^a   Fabbi, Patrizia ^a   Brunelli, Claudio ^a   Spallarossa, Paolo ^a   Altieri, Paola ^a   Rosa, Gianmarco ^a   Spinella, Giovanni ^b   Palombo, Domenico ^b   Arsenescu, Razvan ^c   Arsenescu, Violeta ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

abdominal aortic aneurysm; adiponectin; adipose tissue; angiotensin; aryl hydrocarbon receptor; cardiorenal syndrome; chronic inflammatory diseases; eosinophil; inflammation; macrophage; mast cell inflammatory bowel disease; neutrophil; NK; NKT; uric acid

Indexed keywords

ADIPONECTIN; ANGIOTENSIN; ANGIOTENSIN II; AROMATIC HYDROCARBON RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UREMIC TOXIN; ANGIOTENSIN DERIVATIVE;

ABDOMINAL AORTA ANEURYSM; ADAPTIVE IMMUNITY; ADIPOCYTE; ADIPOSE TISSUE; ATHEROSCLEROSIS; B LYMPHOCYTE; CARDIORENAL SYNDROME; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; COMORBIDITY; DENDRITIC CELL; DIETARY INTAKE; EOSINOPHIL; GRANULOCYTE; HUMAN; IMMUNE RESPONSE; IMPAIRED GLUCOSE TOLERANCE; INFLAMMATORY BOWEL DISEASE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIPOPHILICITY; MACROPHAGE; MAST CELL; MONOCYTE; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; OBESITY; REGULATORY T LYMPHOCYTE; REVIEW; SUBCUTANEOUS FAT; TH1 CELL; WHITE ADIPOSE TISSUE; AGONISTS; ANIMAL; CYTOLOGY; IMMUNE SYSTEM; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY; T LYMPHOCYTE; UREMIA;

ADIPONECTIN; ADIPOSE TISSUE; ANGIOTENSINS; ANIMALS; AORTIC ANEURYSM, ABDOMINAL; CARDIO-RENAL SYNDROME; COMORBIDITY; DENDRITIC CELLS; GRANULOCYTES; HUMANS; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTRA-ABDOMINAL FAT; KILLER CELLS, NATURAL; MACROPHAGES; MONOCYTES; RECEPTORS, ARYL HYDROCARBON; T-LYMPHOCYTES; UREMIA;

EID: 84904730042     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-014-9914-1     Document Type: Review

References (153)

1. Dwyer-Lindgren, L., et al. 2013. Prevalence of physical activity and obesity in US counties, 2001-2011: a road map for action. Population Health Metrics 11(1): 7.
2. McGorrian, C., et al. 2011. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. European Heart Journal 32: 581-589.
3. Rogge, B.P., et al. 2013. Effect of overweight and obesity on cardiovascular events in asymptomatic aortic stenosis (a SEAS substudy). Journal of the American College of Cardiology.
4. Bocca, G., et al. 2013. Insulin resistance and cardiovascular risk factors in 3- to 5-year-old overweight or obese children. Hormone Research in Paediatrics 201-206.
5. Aknc, A., et al. 2013. Association of cardiac changes with serum adiponectin and resistin levels in obese and overweight children. Journal of Cardiovascular Medicine (Hagerstown, Md.) 14(3): 228-234.
6. Smith, S.M., B. Sumar, and K.A. Dixon. 2013. Musculoskeletal pain in overweight and obese children. International Journal of Obesity (London).
7. Pinhas-Hamiel, O., et al. 2013. Advanced bone age and hyperinsulinemia in overweight and obese children. Endocrine Practice 1-20.
8. Salvatore, D., et al. 2013. The prevalence of abnormal metabolic parameters in obese and overweight children. JPEN Journal of Parenteral and Enteral Nutrition.
9. Yun, C.-H., et al. 2012. Pericardial and thoracic peri-aortic adipose tissues contribute to systemic inflammation and calcified coronary atherosclerosis independent of body fat composition, anthropometric measures and traditional cardiovascular risks. European Journal of Radiology 81: 749-756.
10. Rosito, G.A., et al. 2008. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117(5): 605-613.
11. Sogabe, M., et al. 2013. Visceral fat predominance is associated with non-alcoholic fatty liver disease in Japanese women with metabolic syndrome. Hepatology Research.
12. Cordeiro, A.C., et al. 2013. Visceral fat and coronary artery calcification in patients with chronic kidney disease. Nephrology, Dialysis, Transplantation.
13. Ejerblad, E., et al. 2006. Obesity and risk for chronic renal failure. Journal of the American Society of Nephrology 17(6): 1695-1702. (Pubitemid 43794672)
14. Sturm, W., et al. 2009. Influence of visceral obesity and liver fat on vascular structure and function in obese subjects. Obesity (Silver Spring) 17(9): 1783-1788.
15. Galassetti, P. 2012. Inflammation and oxidative stress in obesity, metabolic syndrome, and diabetes. Experimental Diabetes Research 2012: 943706-943706.
16. Permana, P.A., C. Menge, and P.D. Reaven. 2006. Macrophage-secreted factors induce adipocyte inflammation and insulin resistance. Biochemical and Biophysical Research Communications 341(2): 507-514. (Pubitemid 43152134)
17. Pietilainen, K.H., et al. 2011. Association of lipidome remodeling in the adipocyte membrane with acquired obesity in humans. PLoS Biology 9(21666801).
18. Briand, N., et al. 2011. Distinct roles of endothelial and adipocyte caveolin-1 in macrophage infiltration and adipose tissue metabolic activity. Diabetes 60(2): 448-453.
19. Isakson, P., et al. 2009. Impaired preadipocyte differentiation in human abdominal obesity: role of Wnt, tumor necrosis factor-alpha, and inflammation. Diabetes 58(7): 1550-1557.
20. Kanda, H., et al. 2006. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. Journal of Clinical Investigation 116: 1494-1505.
21. Berg, A.H., and P.E. Scherer. 2005. Adipose tissue, inflammation, and cardiovascular disease. Circulation Research 96(9): 939-949. (Pubitemid 40712793)
22. Ouchi, N., et al. 2003. Obesity, adiponectin and vascular inflammatory disease. Current Opinion in Lipidology 14: 561-566. (Pubitemid 41623184)
23. Chinetti-Gbaguidi, G., and B. Staels. 2011. Macrophage polarization in metabolic disorders: functions and regulation. Current Opinion in Lipidology 22: 365-372.
24. Lafontan, M. 2013. Adipose tissue and adipocyte dysregulation. Diabetes & Metabolism.
25. Weiss, T.W., et al. 2011. Adipose tissue pro-inflammatory gene expression is associated with cardiovascular disease. International Journal of Clinical Practice 65: 939-944.
26. Kadowaki, T., et al. 2011. Adiponectin, adiponectin receptors, and epigenetic regulation of adipogenesis. Cold Spring Harbor Symposia on Quantitative Biology 76: 257-265.
27. Hattori, Y., et al. 2008. High molecular weight adiponectin activates AMPK and suppresses cytokine-induced NF-kappaB activation in vascular endothelial cells. FEBS Letters 582: 1719-1724.
28. Haugen, F., and C.A. Drevon. 2007. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology 148(11): 5478-5486. (Pubitemid 350012628)
29. Liu, M., and F. Liu. 2010. Transcriptional and post-translational regulation of adiponectin. Biochemical Journal 425: 41-52.
30. Ryo, M., et al. 2004. Adiponectin as a biomarker of the metabolic syndrome. Circulation Journal 68(11): 975-981. (Pubitemid 39540124)
31. Coughlin, C.C., et al. 2007. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring) 15(3): 640-645. (Pubitemid 46643317)
32. Swarbrick, M.M., et al. 2006. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia 49(11): 2552-2558. (Pubitemid 44559522)
33. Mao, X., et al. 2006. APPL1 binds to adiponectin receptors and mediates adiponectin signalling and function. Nature Cell Biology 8: 516-523.
34. Sag, D., et al. 2008. Adenosine 5′-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. Journal of Immunology 181: 8633-8641.
35. Sasaki, A.T., and R.A. Firtel. 2006. Regulation of chemotaxis by the orchestrated activation of Ras, PI3K, and TOR. European Journal of Cell Biology 85: 873-895. (Pubitemid 44334734)
36. Marchesi, C., P. Paradis, and E.L. Schiffrin. 2008. Role of the renin-angiotensin system in vascular inflammation. Trends in Pharmacological Sciences 29: 367-374.
37. Ishibashi, M., et al. 2004. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circulation Research 94: 1203-1210. (Pubitemid 38659633)
38. Thatcher, S., et al. 2009. The adipose renin-angiotensin system: role in cardiovascular disease. Molecular and Cellular Endocrinology 302: 111-117.
39. Yvan-Charvet, L., and A. Quignard-Boulange. 2011. Role of adipose tissue renin-angiotensin system in metabolic and inflammatory diseases associated with obesity. Kidney International 79(2): 162-168.
40. Makita, S., et al. 2008. Effects of telmisartan on adiponectin levels and body weight in hypertensive patients with glucose intolerance. Metabolism 57: 1473-1478.
41. Trellakis, S., et al. 2012. Low adiponectin, high levels of apoptosis and increased peripheral blood neutrophil activity in healthy obese subjects. Obesity Facts 5: 305-318.
42. Elgazar-Carmon, V., et al. 2008. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. Journal of Lipid Research 49: 1894-1903.
43. Talukdar, S., et al. 2012. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nature Medicine 18: 1407-1412.
44. Kurashima, Y., and H. Kiyono. 2014. New era for mucosal mast cells: their roles in inflammation, allergic immune responses and adjuvant development. Experimental and Molecular Medicine 46: e83.
45. Hirai, S., et al. 2014. Involvement of mast cells in adipose tissue fibrosis. American Journal of Physiology, Endocrinology and Metabolism 306(3): E247-E255.
46. Suurmond, J., et al. 2014. Activation of human basophils by combined toll-like receptor- and FcepsilonRI-triggering can promote Th2 skewing of naive T helper cells. European Journal of Immunology 44(2): 386-396.
47. Zhong, W., et al. 2014. Basophils as a primary inducer of the Th2 immunity in OVA-induced allergic airway inflammation. Immunology.
48. Liu, J., et al. 2009. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nature Medicine 15(8): 940-945.
49. Altintas, M.M., et al. 2011. Mast cells, macrophages, and crown-like structures distinguish subcutaneous from visceral fat in mice. Journal of Lipid Research 52(3): 480-488.
50. Divoux, A., et al. 2012. Mast cells in human adipose tissue: link with morbid obesity, inflammatory status, and diabetes. Journal of Clinical Endocrinology and Metabolism 97(9): E1677-E1685.
51. Marques-Vidal, P., et al. 2013. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clinical Endocrinology 78(2): 232-241.
52. Gerner, R.R., et al. 2013. Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Canadian Journal of Physiology and Pharmacology 91(11): 867-872.
53. Pessin, J.E., and H. Kwon. 2012. How does high-fat diet induce adipose tissue fibrosis? Journal of Investigative Medicine 60(8): 1147-1150.
54. Wu, D., et al. 2011. Eosinophils sustain adipose alternatively activated macrophages associated with glucose homeostasis. Science 332: 243-247.
55. Caspar-Bauguil, S., et al. 2005. Adipose tissues as an ancestral immune organ: site-specific change in obesity. FEBS Letters 579: 3487-3492. (Pubitemid 40897681)
56. Bertola, A., et al. 2012. Identification of adipose tissue dendritic cells correlated with obesity-associated insulin-resistance and inducing Th17 responses in mice and patients. Diabetes 61(9): 2238-2247.
57. Stefanovic-Racic, M., et al. 2012. Dendritic cells promotemacrophage infiltration and comprise a substantial proportion of obesity-associated increases in CD11c + cells in adipose tissue and liver. Diabetes 61(9): 2330-2339.
58. Hagita, S., et al. 2011. Adipose inflammation initiates recruitment of leukocytes to mouse femoral artery: role of adipo-vascular axis in chronic inflammation. PLoS One 6(5): e19871.
59. Chen, Y., et al. 2014. Adipose tissue dendritic cells enhances inflammation by prompting the generation of th17 cells. PLoS One 9(3): e92450.
60. Auffray, C., et al. 2007. Monitoring of blood vessels and tissues by a population of monocytes with patrolling behavior. Science 317: 666-670. (Pubitemid 47229966)
61. Geissmann, F., S. Jung, and D.R. Littman. 2003. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 19: 71-82. (Pubitemid 36859902)
62. Shantsila, A., et al. 2013. Does obesity influence target organ damage and outcomes in patients with malignant phase hypertension? The West Birmingham Malignant Hypertension Project. Hypertension Research 36(6): 546-549.
63. Nockher, W.A., J. Wiemer, and J.E. Scherberich. 2001. Haemodialysis monocytopenia: differential sequestration kinetics of CD14 + CD16+ and CD14++ blood monocyte subsets. Clinical and Experimental Immunology 123: 49-55. (Pubitemid 32118836)
64. Cottam, D.R., et al. 2002. Effect of surgically-induced weight loss on leukocyte indicators of chronic inflammation in morbid obesity. Obesity Surgery 12: 335-342. (Pubitemid 34621025)
65. Rogacev, K.S., et al. 2010. Monocyte heterogeneity in obesity and subclinical atherosclerosis. European Heart Journal 31: 369-376.
66. Schlitt, A., et al. 2004. CD14 + CD16+ monocytes in coronary artery disease and their relationship to serum TNF-alpha levels. Thrombosis and Haemostasis 92: 419-424. (Pubitemid 39172323)
67. Rogacev, K.S., et al. 2011. CD14++CD16+ monocytes and cardiovascular outcome in patients with chronic kidney disease. European Heart Journal 32: 84-92.
68. Heine, G.H., et al. 2008. CD14(++)CD16+ monocytes but not total monocyte numbers predict cardiovascular events in dialysis patients. Kidney International 73: 622-629. (Pubitemid 351264115)
69. Poitou, C., et al. 2011. CD14dimCD16+ and CD14 + CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 31: 2322-2330.
70. Matsunawa, M., et al. 2009. The aryl hydrocarbon receptor activator benzo[a]pyrene enhances vitamin D3 catabolism in macrophages. Toxicological Sciences 109: 50-58.
71. Tsou, C.-L., et al. 2007. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. Journal of Clinical Investigation 117: 902-909. (Pubitemid 46556746)
72. Spite, M., et al. 2011. Deficiency of the leukotriene B4 receptor, BLT-1, protects against systemic insulin resistance in diet-induced obesity. Journal of Immunology 187: 1942-1949.
73. Lynch, L., et al. 2012. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 37(3): 574-587.
74. Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nature Reviews Immunology 5: 953-964. (Pubitemid 41746764)
75. Martinez, F.O., et al. 2008. Macrophage activation and polarization. Frontiers in Bioscience 13: 453-461. (Pubitemid 351599757)
76. Lacasa, D., et al. 2007. Macrophage-secreted factors impair human adipogenesis: involvement of proinflammatory state in preadipocytes. Endocrinology 148: 868-877. (Pubitemid 46143186)
77. Yu, R., et al. 2006. Mesenteric adipose tissue-derived monocyte chemoattractant protein-1 plays a crucial role in adipose tissue macrophage migration and activation in obese mice. Obesity (Silver Spring) 14: 1353-1362. (Pubitemid 46219660)
78. Zhuang, G., et al. 2012. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation 125(23): 2892-2903.
79. Duffaut, C., et al. 2009. Unexpected trafficking of immune cells within the adipose tissue during the onset of obesity. Biochemical and Biophysical Research Communications 384: 482-485.
80. O'Rourke, R.W., et al. 2009. Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. International Journal of Obesity 33(9): 978-990.
81. Rocha, V.Z., et al. 2008. Interferon-gamma, a Th1 cytokine, regulates fat inflammation: a role for adaptive immunity in obesity. Circulation Research 103: 467-476.
82. Taniguchi, M., K. Seino, and T. Nakayama. 2003. The NKT cell system: bridging innate and acquired immunity. Nature Immunology 4(12): 1164-1165. (Pubitemid 37540684)
83. Godfrey, D.I., et al. 2004. NKT cells: what's in a name? Nature Reviews Immunology 4: 231-237. (Pubitemid 38339089)
84. Huh, J.Y., et al. 2013. A novel function of adipocytes in lipid antigen presentation to iNKT cells. Molecular and Cellular Biology 33(2): 328-339.
85. Lynch, L., et al. 2009. Invariant NKT cells and CD1d(+) cells amass in human omentum and are depleted in patients with cancer and obesity. European Journal of Immunology 39(7): 1893-1901.
86. Nishimura, S., et al. 2009. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nature Medicine 15: 914-920.
87. Feuerer, M., et al. 2009. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Medicine 15: 930-939.
88. Duffaut, C., et al. 2009. Interplay between human adipocytes and T lymphocytes in obesity: CCL20 as an adipochemokine and T lymphocytes as lipogenic modulators. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1608-1614.
89. Winer, S., et al. 2009. Normalization of obesity-associated insulin resistance through immunotherapy. Nature Medicine 15(8): 921-929.
90. Khan, I.M., et al. 2014. Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency. Atherosclerosis 233(2): 419-428.
91. Fabbrini, E., et al. 2013. Association between specific adipose tissue CD4+ T-cell populations and insulin resistance in obese individuals. Gastroenterology 145(2): 366.e1-3-374.e1-3.
92. Priceman, S.J., et al. 2013. Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance. Proceedings of the National Academy of Sciences of the United States of America 110(32): 13079-13084.
93. Han, J.M., et al. 2014. Insulin inhibits IL-10-mediated regulatory T cell function: implications for obesity. Journal of Immunology 192(2): 623-629.
94. Poutahidis, T., et al. 2013. Microbial reprogramming inhibits Western diet-associated obesity. PLoS One 8(7): e68596.
95. Zhao, R., et al. 2014. Elevated peripheral frequencies of Th22 cells: a novel potent participant in obesity and type 2 diabetes. PLoS One 9(1): e85770.
96. Thayer, K.A., et al. 2012. Role of environmental chemicals in diabetes and obesity: a National Toxicology Program workshop review. Environmental Health Perspectives 120(6): 779-789.
97. Arsenescu, V., et al. 2008. Polychlorinated biphenyl-77 induces adipocyte differentiation and proinflammatory adipokines and promotes obesity and atherosclerosis. Environmental Health Perspectives 116(6): 761-768. (Pubitemid 351943932)
98. Arsenescu, V., et al. 2011. Polychlorinated biphenyl 77 augments angiotensin II-induced atherosclerosis and abdominal aortic aneurysms in male apolipoprotein E deficient mice. Toxicology and Applied Pharmacology 257: 148-154.
99. Kerley-Hamilton, J.S., et al. 2012. Obesity is mediated by differential aryl hydrocarbon receptor signaling in mice fed a Western diet. Environmental Health Perspectives 120(9): 1252-1259.
100. Kerley-Hamilton, J.S., et al. 2012. Inherent and benzo[a]pyrene-induced differential aryl hydrocarbon receptor signaling greatly affects life span, atherosclerosis, cardiac gene expression, and body and heart growth in mice. Toxicological Sciences 126(2): 391-404.
101. Esser, C. 2012. Biology and function of the aryl hydrocarbon receptor: report of an international and interdisciplinary conference. Archives of Toxicology 86(8): 1323-1329.
102. Littman, D.R., and A.Y. Rudensky. 2010. Th17 and regulatory Tcells in mediating and restraining inflammation. Cell 140: 845-858.
103. Bailey-Downs, L.C., et al. 2013. Aging exacerbates obesity-induced oxidative stress and inflammation in perivascular adipose tissue in mice: a paracrine mechanism contributing to vascular redox dysregulation and inflammation. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 68(7): 780-792.
104. Police, S.B., et al. 2009. Obesity promotes inflammation in periaortic adipose tissue and angiotensin II-induced abdominal aortic aneurysm formation. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1458-1464.
105. Bigorgne, A.E., et al. 2008. Obesity-induced lymphocyte hyperresponsiveness to chemokines: a newmechanismof Fatty liver inflammation in obese mice. Gastroenterology 134(5): 1459-1469.
106. Azimi, A., et al. 2013. Moderate overweight is beneficial and severe obesity detrimental for patients with documented atherosclerotic heart disease. Heart 99(9): 655-660.
107. Ito, S., and M. Yoshida. 2014. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins (Basel) 6(2): 665-678.
108. Ito, S., et al. 2010. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. Journal of Biological Chemistry 285: 38869-38875.
109. Watanabe, I., et al. 2013. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circulation Journal 77: 224-230.
110. Gondouin, B., et al. 2013. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International 84(4): 733-744.
111. Moll, F.L., et al. 2011. Management of abdominal aortic aneurysms clinical practice guidelines of the European society for vascular surgery. European Journal of Vascular and Endovascular Surgery 41(Suppl 1): 1-1.
112. Kent, K.C., et al. 2010. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. Journal of Vascular Surgery 52(3): 539-548.
113. Stackelberg, O., et al. 2013. Obesity and abdominal aortic aneurysm. British Journal of Surgery 100(3): 360-366.
114. Cronin, O., P.J. Walker, and J. Golledge. 2013. The association of obesity with abdominal aortic aneurysm presence and growth. Atherosclerosis 226(2): 321-327.
115. Barandier, C., J.P. Montani, and Z. Yang. 2005. Mature adipocytes and perivascular adipose tissue stimulate vascular smooth muscle cell proliferation: effects of aging and obesity. American Journal of Physiology - Heart and Circulatory Physiology 289(5): H1807-H1813. (Pubitemid 41507326)
116. Golledge, J., et al. 2007. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation 116(20): 2275-2279. (Pubitemid 350100333)
117. Eringa, E.C., et al. 2007. Regulation of vascular function and insulin sensitivity by adipose tissue: focus on perivascular adipose tissue. Microcirculation 14(4-5): 389-402. (Pubitemid 47050030)
118. Schlett, C.L., et al. 2009. Novel measurements of periaortic adipose tissue in comparison to anthropometric measures of obesity, and abdominal adipose tissue. International Journal of Obesity 33(2): 226-232.
119. Chatterjee, T.K., et al. 2009. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circulation Research 104(4): 541-549.
120. Chatterjee, T.K., et al. 2013. Human coronary artery perivascular adipocytes overexpress genes responsible for regulating vascular morphology, inflammation, and hemostasis. Physiological Genomics 45(16): 697-709.
121. Lamers, D., et al. 2011. Oleic acid and adipokines synergize in inducing proliferation and inflammatory signalling in human vascular smoothmuscle cells. Journal of Cellular and Molecular Medicine 15(5): 1177-1188.
122. Arita, Y., et al. 2002. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 105(24): 2893-2898. (Pubitemid 34666104)
123. Maeda, N., et al. 2002. Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nature Medicine 8(7): 731-737. (Pubitemid 34778727)
124. Ohashi, K., et al. 2010. Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype. Journal of Biological Chemistry 285(9): 6153-6160.
125. Aghamohammadzadeh, R., et al. 2013. Effects of bariatric surgery on human small artery function: evidence for reduction in perivascular adipocyte inflammation, and the restoration of normal anticontractile activity despite persistent obesity. Journal of the American College of Cardiology 62(2): 128-135.
126. Ronco, C., et al. 2008. Cardiorenal syndrome. Journal of the American College of Cardiology 52: 1527-1539.
127. Kelly, K.J., et al. 2008. LOX-1 and inflammation: a new mechanism for renal injury in obesity and diabetes. American Journal of Physiology. Renal Physiology 294(5): F1136-F1145.
128. Ramkumar, N., et al. 2004. Association of obesity with inflammation in chronic kidney disease: a cross-sectional study. Journal of Renal Nutrition 14: 201-207. (Pubitemid 39360975)
129. Nolan, E., Y.M. O'Meara, and C. Godson. 2013. Lipid mediators of inflammation in obesity-related glomerulopathy. Nephrology, Dialysis, Transplantation.
130. Iseki, K., et al. 2004. Bodymass index and the risk of development of end-stage renal disease in a screened cohort. Kidney International 65: 1870-1876. (Pubitemid 38591038)
131. Sowers, J.R., A. Whaley-Connell, and M.R. Hayden. 2011. The role of overweight and obesity in the cardiorenal syndrome. Cardiorenal Medicine 1(1): 5-12.
132. Pulakat, L., et al. 2011. The impact of overnutrition on insulin metabolic signaling in the heart and the kidney. Cardiorenal Med 1(2): 102-112.
133. Ma, L.J., et al. 2011. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. American Journal of Physiology. Renal Physiology 300(5): F1203-F1213.
134. Moran, G.W., et al. 2013. The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflammatory Bowel Diseases.
135. Hotamisligil, G.S., and E. Erbay. 2008. Nutrient sensing and inflammation in metabolic diseases. Nature Reviews Immunology 8: 923-934.
136. Kondo, H., et al. 2006. Differential regulation of intestinal lipid metabolism-related genes in obesity-resistant A/J vs. obesity-prone C57BL/6J mice. American Journal of Physiology, Endocrinology and Metabolism 291(5): E1092-E1099.
137. Zulian, A., et al. 2012. Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? Gut 61: 86-94.
138. Arsenescu, V., et al. 2011. Adiponectin and plant-derived mammalian adiponectin homolog exert a protective effect in murine colitis. Digestive Diseases and Sciences 56(10): 2818-2832.
139. Nishihara, T., et al. 2006. Effect of adiponectin on murine colitis induced by dextran sulfate sodium. Gastroenterology 131(3): 853-861. (Pubitemid 44307068)
140. Arsenescu, R., et al. 2011. Role of the xenobiotic receptor in inflammatory bowel disease. Inflammatory Bowel Diseases 17(5): 1149-1162.
141. Gandhi, S., et al. 2012. Are patients with inflammatory bowel disease at increased risk of coronary artery disease? American Journal of Medicine 125: 956-962.
142. Lakatos, P.L., et al. 2011. Serum lipopolysaccharide-binding protein and soluble CD14 are markers of disease activity in patients with Crohn's disease. Inflammatory Bowel Diseases 17(3): 767-777.
143. Mandal, P., et al. 2011. Molecular mechanism for adiponectin-dependent M2 macrophage polarization: link between the metabolic and innate immune activity of full-length adiponectin. Journal of Biological Chemistry 286: 13460-13469.
144. Klinghammer, L., et al. 2013. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis-influence on IP-10, TNF-alpha and MCP-1. Cytokine 62(2): 290-296.
145. Chujo, D., et al. 2007. Telmisartan treatment decreases visceral fat accumulation and improves serum levels of adiponectin and vascular inflammation markers in Japanese hypertensive patients. Hypertension Research 30(12): 1205-1210. (Pubitemid 351176418)
146. Meijers, B.K.I., et al. 2010. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology, Dialysis, Transplantation 25: 219-224.
147. Niwa, T. 2011. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Therapeutic Apheresis and Dialysis 15: 120-124.
148. Konishi, K., et al. 2008. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. Diabetes Research and Clinical Practice 81: 310-315.
149. Nakamura, T., et al. 2004. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney and Blood Pressure Research 27: 121-126. (Pubitemid 38594564)
150. Schroeder, J.C., et al. 2010. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 49: 393-400.
151. Cheng, S., et al. 2010. Adiposity, cardiometabolic risk, and vitamin D status: the Framingham Heart Study. Diabetes 59: 242-248.
152. Rosenblum, J.L., et al. 2012. Calcium and vitamin D supplementation is associated with decreased abdominal visceral adipose tissue in overweight and obese adults. American Journal of Clinical Nutrition 95: 101-108.
153. Poonawalla, A.H., et al. 2013. Adipose tissue MRI for quantitative measurement of central obesity. Journal of Magnetic Resonance Imaging 37: 707-716.